KensaGroup News Release

KensaGroup Launches InVivergy™ to Develop Novel Medical Device and Diagnostic Products

Technologies for Nanoscale Energy Generation and Fertility Analysis

Ithaca NY, October 13, 2009 -- KensaGroup, LLC announces the launch of InVivergy™, which is developing products and solutions for the biomedical marketplace based upon germ-cell specific metabolic pathways. InVivergy's technology platform is founded on the breakthrough research by Dr. Alexander J. Travis, Associate Professor of Reproductive Biology at Cornell University's College of Veterinary Medicine and Baker Institute for Animal Health. InVivergy's™ launch included co-founder Dr. Travis and was done in collaboration with Cornell's Center for Technology, Enterprise and Commercialization and the Baker Institute for Animal Health.

In one application, InVivergy is commercializing a novel energy-producing platform to serve as the power source for implantable medical devices. By modifying germ cell-specific targeting domains, functional glycolytic enzymes from mammalian sperm can be attached to an inorganic chip. Using tethering strategies that mimic the organization of enzymes in the glycolytic pathway, ATP will be produced locally at a nanodevice to provide the source for distributed power generation.

"By metabolizing glucose into ATP, the InVivergy system will supply power for a variety of implantable nanoscale devices," notes Dr. Travis. "Such devices might carry a protein to replace a defective enzyme, or pump an antibiotic or chemotherapeutic drug out at controlled rates precisely where needed to fight an infection or treat a tumor. This could increase the efficiency of treatment while simultaneously reducing the systemic side effects of the drugs."

In parallel with the power applications of the technology, InVivergy is developing an in vitro diagnostic that detects and analyzes a specific biomarker associated with male infertility. The new test mimics changes that mammalian sperm undergo in the woman's reproductive tract that are essential for the sperm to fertilize an egg. Results based on

the assay's novel biomarker readout will assist couples and their clinicians in identifying male infertility and then determining the proper fertility treatment.

"Ten percent of couples in the U.S. have been treated for infertility at an annual cost in excess of $5 billion," commented Tony Eisenhut, President and CEO of KensaGroup. "InVivergy's new fertility test would represent a significant advance over current male fertility diagnostics, which only identify about 50% of the sub-fertile or infertile males tested."

To date, the development of the technology platform has been funded by KensaGroup and research support from the National Institutes of Health and New York State's Center for Life Science Enterprise at Cornell University a NYSTAR program.

About KensaGroup: KensaGroup is a concept stage development firm that builds successful companies around invention, innovation and brands. KG generates significant returns for its shareholders by leveraging C-level operational experience against deep technical knowledge and tight financial management. Since the Company's inception, KensaGroup has evaluated over 3,000 licensable technologies from universities throughout the United States, and has launched several new, high-growth businesses, including Gene Network Sciences, NovaSterilis, Novomer, and iFyber.